Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Islatravir PK/Safety in Transgender Individuals on Hormone Therapy
NCT05130086Phase 2Withdrawn
- Sponsor
- Merck & Co.
- Start
- Oct 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of islatravir in human immunodeficiency virus infection (HIV), sponsored by Merck & Co.. Planned start Oct 2022; status: withdrawn.
02
Drugs
islatravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05130086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05130086.